Chandra J. Panchal

Biography

Dr. Panchal founded Axcelon in 2001 and was a co-founder of Procyon Biopharma Inc., a publicly traded biotechnology company involved in development of wound healing, cancer therapeutic and diagnostic products, which listed on Alberta Stock Exchange in 1998, the TSX in 2000 and changed its name to Ambrilia BioPharma Inc.. He served as Procyon Biopharma Inc.’s Chairman, President and CEO and Ambrilia Biopharma Inc.’s Senior Executive Vice-President, Business Development, Licensing and Intellectual Property in charge of both out-licensing, in-licensing and M&A activities. He retired from Ambrilia Biopharma Inc. in February 2008. Since then, Dr. Panchal has served as a consultant in the biomedical industry and has been an investor in technology. Prior to founding Procyon Biopharma Inc., Dr. Panchal has authored over 50 scientific papers and has edited a book entitled Yeast Strain Selection, published in 1990. Dr. Panchal has been an Adjunct Professor at the University of Western Ontario where he obtained his Ph.D. in biochemical engineering.

Research Interest

Dr. Panchal was a senior scientist/group leader supervising activities related to yeast genetics, fermentations and product development at John Labatt Ltd., a multinational food and beverage company. Dr. Panchal was a director of Procyon Biopharma Inc. from 1989 to 2006. Dr. Panchal is on the board of directors of four public companies and MaRS Innovation.